The USPTO issued a patent covering Enveric Biosciences’ (NASDAQ: ENVB) lead candidate EB-373, a psilocin prodrug under development for the treatment of anxiety disorder.
Issued July 25, the new US patent gives Enveric IP rights for compositions and methods for tryptamine-derived prodrugs utilizing C4-substituted tryptamine derivatives and C4-carbonothiate-substituted tryptamine derivatives.
The company holds that these enhancements to the tryptamine chemical structure could provide a more rapid onset of action, more controlled therapeutic effect and reduced gastrointestinal side-effects compared to traditional psilocin prodrugs like psilocybin.
Enveric’s director and CEO Dr. Joseph Tucker poses that, while several tryptamines -including psilocybin, DMT and 5-MeO-DMT- “have shown therapeutic benefit for the treatment …